Status:

UNKNOWN

HPPH Photodynamic Therapy for Patients With Esophageal Cancer

Lead Sponsor:

Zhejiang Hisun Pharmaceutical Co. Ltd.

Conditions:

Esophageal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Phase I study was to investigate the safety and tolerability of the photosensitizer (PS) 2-\[1-hexyloxyethyl\]-2-devinyl pyropheophorbide-a (HPPH) for injection in patients with Esophageal Cancer. It ...

Detailed Description

The present study is phase I study to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending injection doses of HPPH in Patients with Esophageal Cancer. Up to 30 patients are pl...

Eligibility Criteria

Inclusion

  • 18 years of age or older, Male and female subjects with practicing a highly effective form of birth control, and a signed consent;
  • Subjects who was diagnosed as Esophageal Cancer or carcinoma of gastric cardia by endoscopy and Biopsy pathology at T1-T3 stage.
  • Subjects who could not be taken surgery or chemotherapy; with unsucessful surgery or failed chemotherapy; who had refused surgery and chemotherapy
  • ECOG 0-2, Life expectancy would be more than 3-month

Exclusion

  • Subjects were diagnosed as Tracheoesophageal fistula or Esophageal mediatinal fistula, or more than 60 years old with having three kinds of Heart, Lung, Liver and Kidney commorbities;
  • Hematopoietic WBC \< 3×109/L; HGB \<80g/L; PLT \<80×109/L; PLT \<1.5 times upper limit of normal (ULN)
  • Hepatic TBIL\>1.5ULN, ALT or AST \>2.5 ULN
  • Alkaline phosphatase \> 3 times ULN
  • Uncontrol Hypertension: Bp\>160/100mmHg
  • Uncomtrol Diabetes

Key Trial Info

Start Date :

June 3 2015

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 27 2019

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03757754

Start Date

June 3 2015

End Date

May 27 2019

Last Update

November 29 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Oncology, General Hospital of Beijing Miitary Command of PLA

Beijing, Beijing Municipality, China, 100010